Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update
Reported positive topline results for the Phase 2b RELIEF trial of OCS-02 (licaminlimab) paving the way for potentially the first precision medicine in Dry Eye Disease (DED) Phase 2 ACUITY trial of OCS-05 in acute optic neuritis (AON) is on track for …